ClinVar Miner

Submissions for variant NM_000251.3(MSH2):c.969_970del (p.Gln324fs)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV004018115 SCV004848286 pathogenic Lynch syndrome 2019-10-14 criteria provided, single submitter clinical testing The p.Gln324ValfsX8 (c.969_970delTC) variant in MSH2 has been reported in 4 individuals with colorectal cancer/Lynch syndrome and segregated with disease in 4 affected family members (Sjursen 2010, Hansen 2014, Tanyi 2014, Koder 2017). It was also absent from large population studies. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 324 and leads to a premature termination codon 8 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Another variant, c.970_971delCA (ClinVar ID 91262), resulting in the same amino acid change has been identified in several individuals with Lynch syndrome (Goldberg 2015). Loss of function of the MSH2 gene is an established disease mechanism in autosomal dominant Lynch syndrome. In summary, the p.Gln324ValfsX8 variant meets criteria to be classified as pathogenic for Lynch syndrome. ACMG/AMP criteria applied: PVS1, PS1, PS4_Supporting, PM2, PP1.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.